See the latest news and media coverage for AstraZeneca China. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
In short: AstraZeneca reported higher third-quarter profit and launched a $1.5 billion savings plan to fund its pipeline.
Two innovative therapies make their China debut, cell therapy layout lands in Shanghai Lingang, new drug building construction starts at Wuxi base, and cooperation between Shanghai and UK innovation ecosystems as well as green operations are advanced.
The phase III DeLLphi-305 trial showed that the median overall survival for first-line maintenance therapy reached 21.1 months, compared to 12.7 months in the monotherapy group. Results will be presented at the 2026 ESMO Congress and published in The New England Journal of Medicine.
Tagrisso combined with Tagrisvo reduced the risk of disease progression or death by 45%, and the risk of death by 32%, extending median overall survival by 4.9 months.
Perioperative Inflectra combined with neoadjuvant enfortumab vedotin reduced the recurrence risk of muscle-invasive bladder cancer by 49% and the mortality risk by 42%, with a manageable safety profile.
British pharmaceutical group AstraZeneca announced Friday a 23-percent jump in net profit for the third quarter and a new programme aiming for annual savings of...
AstraZeneca Sets Out $15 Billion China Investment During Starmer Visit BEIJING/LONDON, Jan 29 (Reuters) - UK drugmaker AstraZeneca said on Thursday it would invest $15...
AstraZeneca has announced it's investing $15 billions in China, and said it is partnering with a Chinese biotech to develop weight-loss drugs. The developments come...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Track AstraZeneca China and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to AstraZeneca China and other trending companies.
